Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Viking’s lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being evaluated in a Phase 3 obesity program (VANQUISH-1 and VANQUISH-2) after demonstrating encouraging safety, tolerability, and clinical benefit in earlier trials. The company is also advancing an oral formulation of VK2735. Viking’s second program, VK2809, a selective thyroid hormone receptor beta agonist, achieved significant efficacy in Phase 2 studies for NASH, NAFLD, and dyslipidemia. Viking’s pipeline additionally includes dual amylin and calcitonin receptor agonists (DACRAs) for obesity and VK0214 for X-linked adrenoleukodystrophy, which showed favorable safety and reduced very long-chain fatty acids in Phase 1b. Learn more at www.vikingtherapeutics.com.